UBS

Long/short credit hedge funds can capitalize on looming market dislocations, as opportunities in high-yield and distressed debt ripen amid rising loan and bond default rates, UBS said this week.

We tracked a total of alternative investment 214 deals in June with $90.2 billion in total disclosed value; private credit was the top asset class. Read on for a detailed breakdown and charts.

As renewable energy projects continue to gain traction going into Earth Day, infrastructure deals proliferated. Energy Capital Partners' investment in a Canadian producer of renewable fuels accounted for much of the $356 million in deal activity today. Infrastructure: $300 million ...

The U.S. Federal Reserve reaction to inflation and the ongoing market fallout continues to impact hedge fund strategies, according to UBS Hedge Fund Solutions.

A long-beleaguered portion of the hedge fund industry has gotten a boost in 2022: CTAs. And yes, even investors are extolling commodities as a growing segment of their own portfolios, thanks to ongoing inflation. A good number of commodities funds ...

iCapital announced plans to acquire UBS Fund Advisor, UBS' legacy U.S. alternative investment manager, and the feeder fund platform it manages, AlphaKeys Funds.

Blake Hiltabrand, co-head of event-driven strategies and co-portfolio manager of UBS O'Connor's Merger Arbitrage and Event Driven Strategies, will become global head of UBS O'Connor on Oct. 1 as Kevin Russell's steps down after a seven-year stint at the firm.

iCapital Network, much like the private funds industry it serves, had an incredible 2021 with new funds and clients flocking to its rapidly expanding investment platform. The investment platform aimed at serving the RIA and accredited investor market had grown ...

The iCapital platform and UBS forged a strategic partnership to streamline private investment opportunities across private equity, private debt and real assets for UBS Advisors and their high-net-worth clients in Asia and Switzerland. The clients served will be in major ...

MPM Capital expected to raise $650 million for its second Oncology Impact Fund (OIF 2), which would have been more than enough to snatch the title of largest biotech impact investment fund ever from its own OIF 1, which closed ...